Kidney Cancer

The findings, according to the lead study author from UC San Diego School of Medicine, are a proof of concept and need to be confirmed in a phase 2 trial.

An expert from the University of Texas Southwestern Medical Center in Dallas emphasized that stereotactic radiation provides oncologists with an alternative modality for treating patients with kidney cancer for whom standard ablative surgery is not an option.

The FDA’s decision to grant fast track designation to batiraxcept for treating patients with advanced or metastatic clear cell renal cell carcinoma — a type of kidney cancer — was supported by data from a phase 1b trial.

Comprehensive insight on the factors that help determine optimal first-line therapy for a patient presenting with advanced renal cell carcinoma.

Expert oncologists Matthew Campbell, MD, MS, and Brian Rini, MD, open their discussion on advanced renal cell carcinoma management by defining cornerstone treatment approaches.

The investigational imaging agent 89ZR-DFO-girentuximab met all primary and secondary end points, exceeding pre-determined sensitivity and specificity targets in clear cell renal cell carcinoma, according to findings from the phase 3 ZIRCON study.

Patients with locally advanced/metastatic non–clear cell renal cell carcinoma experienced promising preliminary antitumor activity following treatment with pembrolizumab and lenvatinib in the first line.

Japan’s Ministry of Health, Labor and Welfare approved pembrolizumab for use in 4 indications, including high-risk, early-stage triple-negative breast cancer, stage IIB or IIC melanoma, adjuvant renal cell carcinoma, and recurrent/metastatic cervical cancer.

Findings from the phase 2 KEYNOTE-B61 trial demonstrated promising efficacy with a combination of pembrolizumab and lenvatinib in the frontline treatment of non–clear cell renal cell carcinoma.

Data from the phase 2 LITESPARK-003 trial demonstrated antitumor activity and a well-tolerated safety profile with belzutifan plus cabozantinib in patients with clear cell renal cell carcinoma.

Results from the LITESPARK-003 trial showed continued antitumor activity after 2 years with belzutifan plus cabozantinib.

Findings from the phase 2 BIONIKK trial demonstrated an association between treatment efficacy and increased in situ and immune expression.

The risk for disease progression or death was reduced by 27% with the addition of cabozantinib to nivolumab plus ipilimumab in patients with previously untreated renal cell carcinoma.

The final readout of the phase 2 TITAN-RCC trial highlighted an improvement in responses following an individualized regimen of nivolumab and ipilimumab boost after single-agent nivolumab in patients with advanced renal cell carcinoma.

Patients with advanced clear cell renal cell carcinoma given lenvatinib plus pembrolizumab had sustained overall survival and progression-free survival benefit vs sunitinib, according to updated results of the CLEAR trial.

Patients with localized recall cell carcinoma did not have improved disease-free survival with adjuvant nivolumab plus ipilimumab vs placebo.

Phase 3 data regarding perioperative nivolumab did not show recurrence-free survival benefit, but data from the study may help inform future research.

Data from the phase 3 IMmotion010 trial revealed no benefit of adjuvant atezolizumab vs placebo for resectable renal cell carcinoma.

Patients with clear cell renal cell carcinoma may experience successfully downstaging of venous tumor thrombus extent with neoadjuvant axitinib.

A health-related quality of life survey found similar outcomes between those treated with pembrolizumab plus axitinib vs sunitinib in advanced renal cell carcinoma.

A panel of oncologists reviews a publication by Robert J. Motzer, MD, and colleagues on data from the CLEAR trial examining lenvatinib plus either pembrolizumab or everolimus for advanced renal cell carcinoma.

The primary end point of progression-free survival was met in the phase 3 COSMIC-313 trial which investigated cabozantinib, nivolumab, and ipilimumab in previously untreated, advanced intermediate- or poor-risk renal cell carcinoma.

Experts share their thoughts on recent advances in treatment options for metastatic renal cell carcinoma and comment on emerging data in the field.

Patients with very high-risk renal cell carcinoma experienced a notable relapse-free survival benefit vs placebo following treatment with everolimus.

Lenvatinib plus pembrolizumab decreased the risk of disease progression or death on second-line therapy by 50% compared with sunitinib in the phase 3 CLEAR trial.

Results of the phase 3 EVEREST trial show adjuvant everolimus improved recurrence-free survival for patients with very high-risk renal cell carcinoma.

Interim results from the phase 2 PADRES trial demonstrated that partial nephrectomy may be possible for a subgroup of patients with clear cell renal cell carcinoma with complex masses who received neoadjuvant axitinib.

Results from the phase 2 BIONIKK trial highlighted the feasibility and positive impact of selecting patients with metastatic clear cell renal cell carcinoma for treatment with nivolumab plus or minus ipilimumab and a VEGFR-tyrosine kinase inhibitor based on molecular phenotype.

Robert Alter, MD, comments on the importance of team-based care and frequent, timely communication in managing patients with RCC.

David Aggen, MD, PhD, identifies dosing strategies that may maximize treatment efficacy while minimizing toxicity in patients with kidney cancer.